iBio Q2 EPS Forecast Decreased by Brookline Capital Markets

iBio, Inc. (NASDAQ:IBIO) – Investment analysts at Brookline Capital Markets lowered their Q2 2027 earnings per share (EPS) estimates for iBio in a note issued to investors on Sunday, August 30th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for iBio’s current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for iBio’s Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.31) EPS.

iBio (NASDAQ:IBIO) last released its earnings results on Friday, August 28th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03.

A number of other analysts have also weighed in on IBIO. Raymond James Financial assumed coverage on shares of iBio in a research note on Monday, June 8th. They set an “outperform” rating and a $5.00 price objective for the company. Wall Street Zen downgraded shares of iBio from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Chardan Capital reiterated a “buy” rating and set a $5.00 price target on shares of iBio in a report on Thursday, July 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Wednesday, June 24th. Finally, B. Riley Financial initiated coverage on shares of iBio in a research report on Friday, June 5th. They set a “buy” rating and a $6.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $5.00.

iBio Price Performance

IBIO opened at $1.26 on Wednesday. The firm has a market cap of $62.60 million, a PE ratio of -3.71 and a beta of 1.29. The stock has a 50-day moving average price of $1.47 and a 200-day moving average price of $1.82. iBio has a 1 year low of $0.77 and a 1 year high of $3.82.

Hedge Funds Weigh In On iBio

A number of hedge funds have recently bought and sold shares of IBIO. XTX Topco Ltd bought a new position in iBio during the 4th quarter valued at about $71,000. Persistent Asset Partners Ltd bought a new stake in shares of iBio in the fourth quarter worth approximately $76,000. Susquehanna International Group LLP bought a new stake in shares of iBio in the third quarter worth approximately $37,000. Headlands Technologies LLC raised its holdings in shares of iBio by 333.0% during the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after purchasing an additional 36,463 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of iBio during the first quarter valued at approximately $224,000. Hedge funds and other institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.